PortfoliosLab logoPortfoliosLab logo
ALNY vs. AGX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ALNY vs. AGX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Alnylam Pharmaceuticals, Inc. (ALNY) and Argan, Inc. (AGX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ALNY achieves a -28.05% return, which is significantly lower than AGX's 112.09% return. Over the past 10 years, ALNY has underperformed AGX with an annualized return of 15.09%, while AGX has yielded a comparatively higher 38.10% annualized return.


ALNY

1D
-3.22%
1M
-3.37%
YTD
-28.05%
6M
-38.46%
1Y
-6.52%
3Y*
13.89%
5Y*
14.20%
10Y*
15.09%

AGX

1D
2.51%
1M
-5.57%
YTD
112.09%
6M
85.89%
1Y
217.67%
3Y*
156.33%
5Y*
71.91%
10Y*
38.10%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ALNY vs. AGX - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ALNY
Alnylam Pharmaceuticals, Inc.
-28.05%68.99%22.94%-19.46%40.14%30.48%12.85%57.96%-42.61%239.34%
AGX
Argan, Inc.
112.09%130.61%198.31%30.24%-2.01%-11.64%19.15%8.62%-14.32%-34.26%

Correlation

The correlation between ALNY and AGX is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.11

Correlation (3Y)
Calculated over the trailing 3-year period

0.12

Correlation (5Y)
Calculated over the trailing 5-year period

0.14

Correlation (10Y)
Calculated over the trailing 10-year period

0.13

Correlation (All Time)
Calculated using the full available price history since Jun 2, 2004

0.17

Fundamentals

Market Cap

ALNY:

$39.55B

AGX:

$9.40B

EPS

ALNY:

$4.26

AGX:

$9.73

PE Ratio

ALNY:

67.11

AGX:

68.14

PS Ratio

ALNY:

9.04

AGX:

9.94

PB Ratio

ALNY:

36.78

AGX:

20.34

Total Revenue (TTM)

ALNY:

$4.29B

AGX:

$944.61M

Gross Profit (TTM)

ALNY:

$2.51B

AGX:

$193.68M

EBITDA (TTM)

ALNY:

$729.86M

AGX:

$134.70M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ALNY vs. AGX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ALNY
ALNY Risk / Return Rank: 3232
Overall Rank
ALNY Sharpe Ratio Rank: 3333
Sharpe Ratio Rank
ALNY Sortino Ratio Rank: 2929
Sortino Ratio Rank
ALNY Omega Ratio Rank: 2929
Omega Ratio Rank
ALNY Calmar Ratio Rank: 3535
Calmar Ratio Rank
ALNY Martin Ratio Rank: 3535
Martin Ratio Rank

AGX
AGX Risk / Return Rank: 9393
Overall Rank
AGX Sharpe Ratio Rank: 9494
Sharpe Ratio Rank
AGX Sortino Ratio Rank: 9292
Sortino Ratio Rank
AGX Omega Ratio Rank: 8989
Omega Ratio Rank
AGX Calmar Ratio Rank: 9696
Calmar Ratio Rank
AGX Martin Ratio Rank: 9696
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ALNY vs. AGX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Alnylam Pharmaceuticals, Inc. (ALNY) and Argan, Inc. (AGX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ALNYAGXDifference

Sharpe ratio

Return per unit of total volatility

-0.18

2.94

-3.12

Sortino ratio

Return per unit of downside risk

-0.01

3.47

-3.48

Omega ratio

Gain probability vs. loss probability

1.00

1.43

-0.43

Calmar ratio

Return relative to maximum drawdown

-0.14

8.70

-8.84

Martin ratio

Return relative to average drawdown

-0.27

23.06

-23.32

ALNY vs. AGX - Sharpe Ratio Comparison

The current ALNY Sharpe Ratio is -0.18, which is lower than the AGX Sharpe Ratio of 2.94. The chart below compares the historical Sharpe Ratios of ALNY and AGX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


ALNYAGXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.18

2.94

-3.12

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.29

1.43

-1.14

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.28

0.83

-0.55

Sharpe Ratio (All Time)

Calculated using the full available price history

0.32

0.05

+0.27

Drawdowns

ALNY vs. AGX - Drawdown Comparison

The maximum ALNY drawdown since its inception was -83.58%, smaller than the maximum AGX drawdown of -94.37%. Use the drawdown chart below to compare losses from any high point for ALNY and AGX.


Loading charts...

Drawdown Indicators


ALNYAGXDifference

Max Drawdown

Largest peak-to-trough decline

-83.58%

-94.37%

+10.79%

Max Drawdown (1Y)

Largest decline over 1 year

-42.01%

-24.96%

-17.05%

Max Drawdown (3Y)

Largest decline over 3 years

-42.01%

-43.75%

+1.74%

Max Drawdown (5Y)

Largest decline over 5 years

-42.46%

-43.75%

+1.29%

Max Drawdown (10Y)

Largest decline over 10 years

-59.95%

-54.61%

-5.34%

Current Drawdown

Current decline from peak

-41.75%

-10.50%

-31.25%

Average Drawdown

Average peak-to-trough decline

-30.59%

-48.37%

+17.78%

Ulcer Index

Depth and duration of drawdowns from previous peaks

22.69%

9.42%

+13.27%

Volatility

ALNY vs. AGX - Volatility Comparison

The current volatility for Alnylam Pharmaceuticals, Inc. (ALNY) is 8.50%, while Argan, Inc. (AGX) has a volatility of 14.62%. This indicates that ALNY experiences smaller price fluctuations and is considered to be less risky than AGX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ALNYAGXDifference

Volatility (1M)

Calculated over the trailing 1-month period

8.50%

14.62%

-6.12%

Volatility (6M)

Calculated over the trailing 6-month period

25.96%

55.20%

-29.24%

Volatility (1Y)

Calculated over the trailing 1-year period

36.45%

74.51%

-38.06%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

48.86%

50.60%

-1.74%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

53.69%

46.01%

+7.68%

Dividends

ALNY vs. AGX - Dividend Comparison

ALNY has not paid dividends to shareholders, while AGX's dividend yield for the trailing twelve months is around 0.28%.


PositionTTM20252024202320222021202020192018201720162015
AGX
Argan, Inc.
0.28%0.52%0.93%2.24%2.71%1.94%7.31%2.49%1.98%4.44%1.42%2.16%
ALNY
Alnylam Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

ALNY vs. AGX - Financials Comparison

This section allows you to compare key financial metrics between Alnylam Pharmaceuticals, Inc. and Argan, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


200.00M400.00M600.00M800.00M1.00B1.20B20222023202420252026
1.17B
262.05M
(ALNY) Total Revenue
(AGX) Total Revenue
Values in USD except per share items

ALNY vs. AGX - Profitability Comparison

The chart below illustrates the profitability comparison between Alnylam Pharmaceuticals, Inc. and Argan, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%202220232024202520260
25.0%
Portfolio components
ALNY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Alnylam Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 1.17B. Therefore, the gross margin over that period was 0.0%.

AGX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Argan, Inc. reported a gross profit of 65.60M and revenue of 262.05M. Therefore, the gross margin over that period was 25.0%.

ALNY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Alnylam Pharmaceuticals, Inc. reported an operating income of 268.64M and revenue of 1.17B, resulting in an operating margin of 23.0%.

AGX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Argan, Inc. reported an operating income of 47.67M and revenue of 262.05M, resulting in an operating margin of 18.2%.

ALNY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Alnylam Pharmaceuticals, Inc. reported a net income of 205.99M and revenue of 1.17B, resulting in a net margin of 17.7%.

AGX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Argan, Inc. reported a net income of 49.21M and revenue of 262.05M, resulting in a net margin of 18.8%.


Frequently Asked Questions


ALNY and AGX have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AGX has higher volatility (14.62%) compared to ALNY (8.50%). In terms of maximum drawdown, ALNY dropped -83.58% vs AGX's -94.37%.

AGX currently has the higher Sharpe Ratio (2.94 vs -0.18), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ALNY and AGX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer